Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Friday, plunged -3.04% from the previous trading day, before settling in for the closing price of $5.27. Within the past 52 weeks, XERS’s price has moved between $2.10 and $6.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 40.01%. The company achieved an average annual earnings per share of 80.00%. With a float of $147.58 million, this company’s outstanding shares have now reached $156.01 million.
Let’s determine the extent of company efficiency that accounts for 394 employees. In terms of profitability, gross margin is 80.99%, operating margin of -10.11%, and the pretax margin is -21.41%.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 7.85%, while institutional ownership is 54.43%. The most recent insider transaction that took place on Jun 13 ’25, was worth 109,475. In this transaction an insider of this company bought 25,000 shares at a rate of $4.38, taking the stock ownership to the 1,708,585 shares. Before that another transaction happened on May 09 ’25, when Company’s Director proposed sale 56,667 for $4.90, making the entire transaction worth $277,668.
Xeris Biopharma Holdings Inc (XERS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 80.00% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.17 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.30, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Looking closely at Xeris Biopharma Holdings Inc (NASDAQ: XERS), its last 5-days average volume was 2.2 million, which is a drop from its year-to-date volume of 2.5 million. As of the previous 9 days, the stock’s Stochastic %D was 83.88%.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 61.75%, which indicates a significant decrease from 71.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.21 in the past 14 days, which was lower than the 0.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.73, while its 200-day Moving Average is $3.94. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $5.22. Second resistance stands at $5.34. The third major resistance level sits at $5.40. If the price goes on to break the first support level at $5.05, it is likely to go to the next support level at $4.99. Should the price break the second support level, the third support level stands at $4.87.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 818.39 million based on 156,385K outstanding shares. Right now, sales total 203,070 K and income totals -54,840 K. The company made 60,120 K in profit during its latest quarter, and -9,220 K in sales during its previous quarter.
